About Elisabeth Semmelrock

This author has not yet filled in any details.
So far Elisabeth Semmelrock has created 54 blog entries.
31 07, 2026

TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

2026-07-31T08:34:40+02:00July 31st, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA|0 Comments

Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to deliver a lecture on microRNA biomarker discovery, validation, and clinical application, titled: "microRNAs as Biomarkers: Discovery, Validation, and the Path to Clinical Application" Participants will: Understand what constitutes a clinically useful biomarker and how signal-to-noise ratio and pre-analytical, analytical, and biological variability impact biomarker study design Learn how small RNA sequencing (next-generation sequencing, NGS) [...]

20 07, 2026

Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing

2026-07-20T09:10:58+02:00July 20th, 2026|Biomarker Discovery, biomarkers, microRNA, microRNA services, microRNAs|0 Comments

New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose of zoledronic acid. Background: A prior trial showed that a single systemic dose of zoledronic acid reduces retear rates in non-osteoporotic patients after rotator cuff repair. This follow-up study investigated the underlying biology by profiling circulating miRNAs linked to inflammation, fibrosis, and tendon-to-bone healing. Design: In a single-center, randomized, placebo-controlled, triple-blinded phase II trial, [...]

3 06, 2026

Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

2026-06-03T10:23:09+02:00June 3rd, 2026|microRNA, microRNA services, microRNAs, miND, miND spike ins, miND spike-in, NGS, small RNA-sequencing, smallRNA|Comments Off on Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly comparable. This is exactly where TAmiRNA's miND® Spike-ins come in. In our new miND® Spike-ins FAQ Guide, we answer the three most frequently asked questions we receive from researchers and CRO partners. How are spike-ins used? miND® Spike-ins are added directly to extracted RNA immediately before library preparation. This means they travel through the [...]

8 05, 2026

A New Milestone in EV-Based Therapies Research

2026-05-08T11:11:22+02:00May 8th, 2026|EV characterization, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, Parkinson’s Disease|Comments Off on A New Milestone in EV-Based Therapies Research

A major hurdle in EV-based therapies is the "yield gap" — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs. In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA scientists, addressed this challenge head-on. Together, we applied deep molecular fingerprinting and in vivo potency studies to validate a new large-scale production protocol for Parkinson’s Disease (PD) therapies. By leveraging our specialized transcriptomic and proteomic pipelines, we analyzed how production and purification methods shape the EV "message": ✅ 𝟯𝗗 𝘃𝘀. 𝟮𝗗 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻: Our analysis [...]

24 04, 2026

New publication in Biomaterials

2026-04-24T11:54:56+02:00April 24th, 2026|EV characterization, exosomes, extracellular vesicle, Macrophages, microRNA, microRNA services, microRNAs, RegenerativeMedicine, WoundHealing|Comments Off on New publication in Biomaterials

Huge congrats to Cansu Gorgun and the teams at Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin on their new publication in Biomaterials! This study is a fascinating look at how we can "train" macrophages to do two things at once. By reprogramming their metabolism, the team produced hybrid M1/M2 extracellular vesicles — a "dual-action" package that combines pro-inflammatory and pro-healing signals. We were lucky enough to support this work at 𝗧𝗔𝗺𝗶𝗥𝗡𝗔 by characterizing the EV miRNA cargo and looking into the functional implications of these hybrid vesicles. It’s a clever, elegant approach that opens new possibilities for smarter wound healing, tissue repair, and cell-free regenerative therapies. Fantastic work by everyone involved! TAmiRNA EV [...]

11 03, 2026

TAmiRNA @ RNA Leaders Europe Conference

2026-03-11T10:10:00+01:00March 11th, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, regulatory developments, and commercialization strategies in the rapidly evolving RNA field. As a specialized provider of RNA-focused services, TAmiRNA supports partners worldwide with comprehensive solutions ranging from RNA profiling and biomarker discovery to advanced bioinformatics and customized data analysis. The conference offers an excellent platform to exchange insights, explore collaborations, and discuss how cutting-edge [...]

2 03, 2026

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

2026-03-02T10:12:31+01:00March 2nd, 2026|biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools. This case-control study investigated previously reported circulating miRNAs in: 24 adolescents with type [...]

21 01, 2026

New white paper with RoosterBio on omics-tools for EV characterization

2026-01-22T11:53:45+01:00January 21st, 2026|EV characterization, exosomes, extracellular vesicle, miND, miND spike-in, NGS, sequencing, small RNA-sequencing|Comments Off on New white paper with RoosterBio on omics-tools for EV characterization

In this white paper, TAmiRNA and RoosterBio present a comprehensive small RNA-sequencing–based characterization of mesenchymal stem cell (MSC)–derived exosomes produced using RoosterBio’s standardized, xeno-free manufacturing platform. The study was designed to assess both the analytical robustness of TAmiRNA’s miND® small RNA-sequencing workflow and the biological relevance of microRNA cargo profiling as an advanced “omics-based” characterization strategy for therapeutic extracellular vesicles (EVs). Using technical replicates and independent EV vials, we demonstrate that small RNA-sequencing performed with the miND® workflow yields highly reproducible and quantitatively consistent microRNA profiles, confirming the robustness of the analytical pipeline and the stability of RoosterBio’s EV products. In addition, comparative profiling of EVs derived from umbilical cord, bone marrow, and adipose tissue MSCs revealed [...]

7 01, 2026

TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

2026-01-21T08:39:17+01:00January 7th, 2026|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

Research conducted by TAmiRNA in collaboration with the Michael Ogon Laboratory (Orthopädisches Spital Speising) on microRNA-based biomarkers for the early detection of periprosthetic joint infections (PJI) was recently featured on Wien Heute, one of Austria’s most widely viewed regional television news programs (ORF, January 3, 2026). The coverage highlights both the clinical relevance of the problem and the translational potential of novel molecular diagnostic approaches. Periprosthetic joint infections are among the most serious complications following hip and knee arthroplasty. Although the incidence is estimated at approximately 1-10%, PJIs are associated with substantial morbidity, prolonged treatment, and high healthcare costs. A major challenge in clinical practice remains the timely and reliable differentiation between infected and non-infected implants, particularly [...]

4 12, 2025

Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

2025-12-04T11:05:09+01:00December 4th, 2025|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

New research highlights the potential of circulating miRNAs as biomarkers for joint degeneration A new peer-reviewed study has been published in the International Journal of Molecular Sciences (IJMS): “Synovial Fluid and Serum MicroRNA Signatures in Equine Osteoarthritis.” This work provides important insights into how microRNAs (miRNAs) in serum and synovial fluid reflect the presence of osteoarthritis (OA) in horses. 🎯 Study Aim The researchers sought to identify disease-associated miRNAs that differ between healthy horses and horses with osteoarthritis. Their goal was to uncover molecular signatures that could support the development of novel biomarkers for early detection and monitoring of OA. 🔬 Methods Serum and synovial fluid samples were collected from healthy controls (n = 4) and horses [...]

Go to Top